Chimeric Therapeutics Limited

ASX:CHM Stok Raporu

Piyasa değeri: AU$8.1m

Chimeric Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Chimeric Therapeutics has a total shareholder equity of A$2.5M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$15.3M and A$12.8M respectively.

Anahtar bilgiler

0%

Borç/özkaynak oranı

AU$0

Borç

Faiz karşılama oranın/a
NakitAU$3.05m
EşitlikAU$2.47m
Toplam yükümlülüklerAU$12.80m
Toplam varlıklarAU$15.27m

Son finansal sağlık güncellemeleri

Recent updates

Here's Why We're Watching Chimeric Therapeutics' (ASX:CHM) Cash Burn Situation

Oct 13
Here's Why We're Watching Chimeric Therapeutics' (ASX:CHM) Cash Burn Situation

Here's Why We're Watching Chimeric Therapeutics' (ASX:CHM) Cash Burn Situation

Feb 23
Here's Why We're Watching Chimeric Therapeutics' (ASX:CHM) Cash Burn Situation

We Think Chimeric Therapeutics (ASX:CHM) Needs To Drive Business Growth Carefully

Oct 20
We Think Chimeric Therapeutics (ASX:CHM) Needs To Drive Business Growth Carefully

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: CHM's short term assets (A$3.2M) do not cover its short term liabilities (A$10.1M).

Uzun Vadeli Yükümlülükler: CHM's short term assets (A$3.2M) exceed its long term liabilities (A$2.7M).


Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: CHM is debt free.

Borcun Azaltılması: CHM had no debt 5 years ago.


Bilanço


Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: CHM has sufficient cash runway for 5 months based on last reported free cash flow, but has since raised additional capital.

Tahmini Nakit Akışı: CHM is forecast to have sufficient cash runway for 4 months based on free cash flow estimates, but has since raised additional capital.


Sağlıklı şirketleri keşfedin